Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Lung Diseases
- Neoplasms
- Non -Small Cell Lung Cancer
- Respiratory Tract Diseases
- Thoracic Neoplasms
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC
Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC
Tracking Information
- NCT #
- NCT04371796
- Collaborators
- Innovent Biologics, Inc.
- Investigators
- Principal Investigator: Juan Li, MD Sichuan Cancer Hospital and Research Institute
Get Well Soon